{"filing":{"accession_number":"0001193125-26-274410","cik":"0001781174","ticker":"ACRV","company_name":"Acrivon Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-17","report_date":null,"primary_document":"acrv-20260617.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1781174/000119312526274410/acrv-20260617.htm"},"events":[{"id":11659,"run_id":10243,"accession_number":"0001193125-26-274410","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"Acrivon held its Annual Meeting of Stockholders and disclosed voting results for three proposals: election of two Class I directors (Michael Tomsicek and Charles Baum), ratification of PricewaterhouseCoopers LLP as independent auditor, and approval of the Amended and Restated 2022 Equity Incentive Plan. All three proposals passed with substantial majorities.","company_name":"Acrivon Therapeutics, Inc.","ticker":"ACRV","filing_date":"2026-06-17","submitted_at":null,"items":[{"id":8304,"accession_number":"0001193125-26-274410","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure centers on stockholder approval of the Amended and Restated 2022 Equity Incentive Plan, which governs compensatory arrangements (equity awards including stock options, RSUs, and performance awards) for employees, directors, and consultants. The filing details the plan's purposes, authorized share reserve (8,606,723 shares with a 3,000,000 share increase approved at the Annual Meeting), and automatic annual increases through 2032. This is a material compensation plan amendment requiring stockholder approval under Item 5.02(e).","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-17T21:29:08.087278+00:00","company_name":"","ticker":null,"filing_date":""},{"id":8305,"accession_number":"0001193125-26-274410","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"This is a classic Item 5.07 disclosure reporting the results of an Annual Meeting of Stockholders. The filing presents voting outcomes for three proposals: election of two Class I directors (Michael Tomsicek and Charles Baum), ratification of PricewaterhouseCoopers LLP as independent auditor, and approval of the Amended and Restated 2022 Equity Incentive Plan. All three proposals passed with substantial majorities, and the disclosure includes vote tallies (For/Against/Abstain/Broker Non-Votes) for each item, which is the standard format for shareholder vote results under Item 5.07.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-17T21:29:08.087278+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":8304,"accession_number":"0001193125-26-274410","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure centers on stockholder approval of the Amended and Restated 2022 Equity Incentive Plan, which governs compensatory arrangements (equity awards including stock options, RSUs, and performance awards) for employees, directors, and consultants. The filing details the plan's purposes, authorized share reserve (8,606,723 shares with a 3,000,000 share increase approved at the Annual Meeting), and automatic annual increases through 2032. This is a material compensation plan amendment requiring stockholder approval under Item 5.02(e).","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-17T21:29:08.087278+00:00","company_name":"Acrivon Therapeutics, Inc.","ticker":"ACRV","filing_date":"2026-06-17"},{"id":8305,"accession_number":"0001193125-26-274410","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"This is a classic Item 5.07 disclosure reporting the results of an Annual Meeting of Stockholders. The filing presents voting outcomes for three proposals: election of two Class I directors (Michael Tomsicek and Charles Baum), ratification of PricewaterhouseCoopers LLP as independent auditor, and approval of the Amended and Restated 2022 Equity Incentive Plan. All three proposals passed with substantial majorities, and the disclosure includes vote tallies (For/Against/Abstain/Broker Non-Votes) for each item, which is the standard format for shareholder vote results under Item 5.07.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-17T21:29:08.087278+00:00","company_name":"Acrivon Therapeutics, Inc.","ticker":"ACRV","filing_date":"2026-06-17"}]}